BridgeMD
Evaluation of the decolonization rate and acceptance of a complete nasal decolonization kit with povidone iodine for MRSA patients
EU CTIS ID: 2022-500642-25-00
What this study is testing
Estimate the MRSA decolonization rate 6 hours after nasal application of a topical PVP-I gel.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients readmitted at the Nantes University Hospital and detected to be already MRSA positive by nasal systematic screening
- MRSA patients with length of hospital stay > 4 days
- Patient older than 18 years and informed about the study
- Patients who provide their written informed consent
- Patient affiliated with French social security system or beneficiary from such system
You likely can't join if
- Patient < 18 years
- Patients with damaged skin or mucous
- Use of mercurial antiseptic during the study
- Patients with a history of thyroid disorders
- Patient with known intolerance to PVD-I derivatives or excipients
- Known MRSA colonized patient managed in outpatient or inpatient care but with a negative nasal screen
See the full eligibility criteria
- Patients readmitted at the Nantes University Hospital and detected to be already MRSA positive by nasal systematic screening
- MRSA patients with length of hospital stay > 4 days
- Patient older than 18 years and informed about the study
- Patients who provide their written informed consent
- Patient affiliated with French social security system or beneficiary from such system
- Patient < 18 years
- Patients with damaged skin or mucous
- Use of mercurial antiseptic during the study
- Patients with a history of thyroid disorders
- Patient with known intolerance to PVD-I derivatives or excipients
- Known MRSA colonized patient managed in outpatient or inpatient care but with a negative nasal screen
- New patient with MRSA infection (this patient can be included later in case of hospital readmission)
- Pregnancy or breastfeeding, patient with childbearing potential that refused acceptable contraceptive method (Acceptable birth control methods that result in a failure rate of more than 1% per year include: progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, male or female condom with or without spermicide, cap, diaphragm or sponge with spermicide, a combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods) are also considered acceptable, but not highly effective, birth control methods)
- Adults under guardianship or trusteeship
- Patients under juridical protection
- Patients with a known risk of allergy to povidone iodine
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.